HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial
Latest Information Update: 01 Mar 2024
At a glance
- Drugs V 503 (Primary)
- Indications Anal cancer; Carcinoma; Squamous cell cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 24 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 23 Oct 2022 Primary endpoint has not been met, (Time to persistent high-risk infection among vaccine compared with placebo recipients), as per presented at the IDWeek 2022
- 20 Apr 2022 Planned End Date changed from 31 Jan 2023 to 31 Jul 2023.